Libtayo Longer-Term Data Show Increased Overall Survival Benefit

Nearly four years of follow-up showed a further reduction in the risk of death from 14% to 37% among patients initially treated with Libtayo, despite 88% crossover from the placebo arm upon recurrence. The analysis also confirmed a sustained disease-free survival benefit.